nodes	percent_of_prediction	percent_of_DWPC	metapath
Guanabenz—Guanfacine—CYP3A4—bone cancer	0.0204	1	CrCbGaD
Guanabenz—NISCH—Hypothetical Network for Drug Addiction—GRM1—bone cancer	0.0127	0.276	CbGpPWpGaD
Guanabenz—CYP1A2—Lidocaine metabolism—CYP3A4—bone cancer	0.0045	0.098	CbGpPWpGaD
Guanabenz—Face oedema—Epirubicin—bone cancer	0.00228	0.00244	CcSEcCtD
Guanabenz—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.00227	0.00244	CcSEcCtD
Guanabenz—Oedema—Cisplatin—bone cancer	0.00226	0.00242	CcSEcCtD
Guanabenz—Infection—Cisplatin—bone cancer	0.00225	0.00241	CcSEcCtD
Guanabenz—Hypoglycaemia—Doxorubicin—bone cancer	0.00224	0.0024	CcSEcCtD
Guanabenz—Cardiac failure—Doxorubicin—bone cancer	0.00224	0.0024	CcSEcCtD
Guanabenz—Nervous system disorder—Cisplatin—bone cancer	0.00222	0.00238	CcSEcCtD
Guanabenz—Thrombocytopenia—Cisplatin—bone cancer	0.00221	0.00237	CcSEcCtD
Guanabenz—Tachycardia—Cisplatin—bone cancer	0.00221	0.00236	CcSEcCtD
Guanabenz—Dehydration—Epirubicin—bone cancer	0.0022	0.00235	CcSEcCtD
Guanabenz—Skin disorder—Cisplatin—bone cancer	0.0022	0.00235	CcSEcCtD
Guanabenz—Hyponatraemia—Doxorubicin—bone cancer	0.0022	0.00235	CcSEcCtD
Guanabenz—Liver function test abnormal—Epirubicin—bone cancer	0.00218	0.00234	CcSEcCtD
Guanabenz—Dry skin—Epirubicin—bone cancer	0.00217	0.00232	CcSEcCtD
Guanabenz—Orthostatic hypotension—Epirubicin—bone cancer	0.00216	0.00231	CcSEcCtD
Guanabenz—Anorexia—Cisplatin—bone cancer	0.00216	0.00231	CcSEcCtD
Guanabenz—Hypokalaemia—Epirubicin—bone cancer	0.00215	0.0023	CcSEcCtD
Guanabenz—Breast disorder—Epirubicin—bone cancer	0.00214	0.00229	CcSEcCtD
Guanabenz—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.00213	0.00228	CcSEcCtD
Guanabenz—Hypotension—Cisplatin—bone cancer	0.00211	0.00226	CcSEcCtD
Guanabenz—Face oedema—Doxorubicin—bone cancer	0.00211	0.00226	CcSEcCtD
Guanabenz—Abdominal discomfort—Methotrexate—bone cancer	0.00209	0.00224	CcSEcCtD
Guanabenz—Gastritis—Epirubicin—bone cancer	0.00209	0.00224	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Cisplatin—bone cancer	0.00206	0.00221	CcSEcCtD
Guanabenz—Abdominal distension—Epirubicin—bone cancer	0.00206	0.0022	CcSEcCtD
Guanabenz—Influenza—Epirubicin—bone cancer	0.00204	0.00219	CcSEcCtD
Guanabenz—Dehydration—Doxorubicin—bone cancer	0.00203	0.00218	CcSEcCtD
Guanabenz—Paraesthesia—Cisplatin—bone cancer	0.00203	0.00218	CcSEcCtD
Guanabenz—Upper respiratory tract infection—Methotrexate—bone cancer	0.00203	0.00217	CcSEcCtD
Guanabenz—Liver function test abnormal—Doxorubicin—bone cancer	0.00202	0.00216	CcSEcCtD
Guanabenz—Dyspnoea—Cisplatin—bone cancer	0.00202	0.00216	CcSEcCtD
Guanabenz—Dry skin—Doxorubicin—bone cancer	0.002	0.00215	CcSEcCtD
Guanabenz—Orthostatic hypotension—Doxorubicin—bone cancer	0.002	0.00214	CcSEcCtD
Guanabenz—Hypokalaemia—Doxorubicin—bone cancer	0.00199	0.00213	CcSEcCtD
Guanabenz—Breast disorder—Doxorubicin—bone cancer	0.00198	0.00212	CcSEcCtD
Guanabenz—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00197	0.00211	CcSEcCtD
Guanabenz—Decreased appetite—Cisplatin—bone cancer	0.00197	0.00211	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Cisplatin—bone cancer	0.00195	0.00209	CcSEcCtD
Guanabenz—Infestation NOS—Methotrexate—bone cancer	0.00195	0.00208	CcSEcCtD
Guanabenz—Infestation—Methotrexate—bone cancer	0.00195	0.00208	CcSEcCtD
Guanabenz—Gastritis—Doxorubicin—bone cancer	0.00194	0.00207	CcSEcCtD
Guanabenz—Pain—Cisplatin—bone cancer	0.00193	0.00207	CcSEcCtD
Guanabenz—Abdominal distension—Doxorubicin—bone cancer	0.0019	0.00204	CcSEcCtD
Guanabenz—Upper respiratory tract infection—Epirubicin—bone cancer	0.0019	0.00203	CcSEcCtD
Guanabenz—Influenza—Doxorubicin—bone cancer	0.00189	0.00202	CcSEcCtD
Guanabenz—Feeling abnormal—Cisplatin—bone cancer	0.00186	0.002	CcSEcCtD
Guanabenz—Weight increased—Epirubicin—bone cancer	0.00186	0.00199	CcSEcCtD
Guanabenz—Weight decreased—Epirubicin—bone cancer	0.00185	0.00198	CcSEcCtD
Guanabenz—Hyperglycaemia—Epirubicin—bone cancer	0.00184	0.00197	CcSEcCtD
Guanabenz—Infestation—Epirubicin—bone cancer	0.00182	0.00195	CcSEcCtD
Guanabenz—Infestation NOS—Epirubicin—bone cancer	0.00182	0.00195	CcSEcCtD
Guanabenz—Body temperature increased—Cisplatin—bone cancer	0.00179	0.00191	CcSEcCtD
Guanabenz—Upper respiratory tract infection—Doxorubicin—bone cancer	0.00176	0.00188	CcSEcCtD
Guanabenz—Haemoglobin—Methotrexate—bone cancer	0.00176	0.00188	CcSEcCtD
Guanabenz—Haemorrhage—Methotrexate—bone cancer	0.00175	0.00187	CcSEcCtD
Guanabenz—Weight increased—Doxorubicin—bone cancer	0.00172	0.00184	CcSEcCtD
Guanabenz—Weight decreased—Doxorubicin—bone cancer	0.00171	0.00183	CcSEcCtD
Guanabenz—Hyperglycaemia—Doxorubicin—bone cancer	0.0017	0.00183	CcSEcCtD
Guanabenz—Infestation—Doxorubicin—bone cancer	0.00169	0.0018	CcSEcCtD
Guanabenz—Infestation NOS—Doxorubicin—bone cancer	0.00169	0.0018	CcSEcCtD
Guanabenz—Hypersensitivity—Cisplatin—bone cancer	0.00167	0.00178	CcSEcCtD
Guanabenz—Erythema multiforme—Methotrexate—bone cancer	0.00165	0.00177	CcSEcCtD
Guanabenz—CYP1A2—Aflatoxin B1 metabolism—CYP3A4—bone cancer	0.00165	0.036	CbGpPWpGaD
Guanabenz—Haemoglobin—Epirubicin—bone cancer	0.00164	0.00176	CcSEcCtD
Guanabenz—Haemorrhage—Epirubicin—bone cancer	0.00163	0.00175	CcSEcCtD
Guanabenz—Eye disorder—Methotrexate—bone cancer	0.00163	0.00175	CcSEcCtD
Guanabenz—Tinnitus—Methotrexate—bone cancer	0.00163	0.00174	CcSEcCtD
Guanabenz—Asthenia—Cisplatin—bone cancer	0.00162	0.00174	CcSEcCtD
Guanabenz—Oedema peripheral—Epirubicin—bone cancer	0.00161	0.00172	CcSEcCtD
Guanabenz—Connective tissue disorder—Epirubicin—bone cancer	0.00161	0.00172	CcSEcCtD
Guanabenz—Immune system disorder—Methotrexate—bone cancer	0.00158	0.00169	CcSEcCtD
Guanabenz—Mediastinal disorder—Methotrexate—bone cancer	0.00157	0.00169	CcSEcCtD
Guanabenz—Chills—Methotrexate—bone cancer	0.00157	0.00168	CcSEcCtD
Guanabenz—Diarrhoea—Cisplatin—bone cancer	0.00155	0.00166	CcSEcCtD
Guanabenz—Erythema multiforme—Epirubicin—bone cancer	0.00155	0.00166	CcSEcCtD
Guanabenz—Eye disorder—Epirubicin—bone cancer	0.00153	0.00164	CcSEcCtD
Guanabenz—Tinnitus—Epirubicin—bone cancer	0.00152	0.00163	CcSEcCtD
Guanabenz—Malnutrition—Methotrexate—bone cancer	0.00152	0.00163	CcSEcCtD
Guanabenz—Erythema—Methotrexate—bone cancer	0.00152	0.00163	CcSEcCtD
Guanabenz—Haemoglobin—Doxorubicin—bone cancer	0.00152	0.00163	CcSEcCtD
Guanabenz—Haemorrhage—Doxorubicin—bone cancer	0.00151	0.00162	CcSEcCtD
Guanabenz—Oedema peripheral—Doxorubicin—bone cancer	0.00149	0.0016	CcSEcCtD
Guanabenz—Connective tissue disorder—Doxorubicin—bone cancer	0.00149	0.00159	CcSEcCtD
Guanabenz—CYP1A2—Oxidation by Cytochrome P450—CYP4V2—bone cancer	0.00148	0.0322	CbGpPWpGaD
Guanabenz—Immune system disorder—Epirubicin—bone cancer	0.00148	0.00158	CcSEcCtD
Guanabenz—Mediastinal disorder—Epirubicin—bone cancer	0.00147	0.00158	CcSEcCtD
Guanabenz—Back pain—Methotrexate—bone cancer	0.00147	0.00158	CcSEcCtD
Guanabenz—Chills—Epirubicin—bone cancer	0.00147	0.00157	CcSEcCtD
Guanabenz—Vomiting—Cisplatin—bone cancer	0.00144	0.00154	CcSEcCtD
Guanabenz—Vision blurred—Methotrexate—bone cancer	0.00143	0.00153	CcSEcCtD
Guanabenz—Erythema multiforme—Doxorubicin—bone cancer	0.00143	0.00153	CcSEcCtD
Guanabenz—Rash—Cisplatin—bone cancer	0.00143	0.00153	CcSEcCtD
Guanabenz—Dermatitis—Cisplatin—bone cancer	0.00142	0.00153	CcSEcCtD
Guanabenz—Malnutrition—Epirubicin—bone cancer	0.00142	0.00152	CcSEcCtD
Guanabenz—Erythema—Epirubicin—bone cancer	0.00142	0.00152	CcSEcCtD
Guanabenz—Eye disorder—Doxorubicin—bone cancer	0.00141	0.00151	CcSEcCtD
Guanabenz—Ill-defined disorder—Methotrexate—bone cancer	0.00141	0.00151	CcSEcCtD
Guanabenz—Tinnitus—Doxorubicin—bone cancer	0.00141	0.00151	CcSEcCtD
Guanabenz—Anaemia—Methotrexate—bone cancer	0.00141	0.00151	CcSEcCtD
Guanabenz—Flatulence—Epirubicin—bone cancer	0.0014	0.0015	CcSEcCtD
Guanabenz—Tension—Epirubicin—bone cancer	0.0014	0.0015	CcSEcCtD
Guanabenz—Nervousness—Epirubicin—bone cancer	0.00138	0.00148	CcSEcCtD
Guanabenz—Back pain—Epirubicin—bone cancer	0.00138	0.00147	CcSEcCtD
Guanabenz—Malaise—Methotrexate—bone cancer	0.00137	0.00147	CcSEcCtD
Guanabenz—Muscle spasms—Epirubicin—bone cancer	0.00137	0.00147	CcSEcCtD
Guanabenz—Immune system disorder—Doxorubicin—bone cancer	0.00137	0.00146	CcSEcCtD
Guanabenz—Mediastinal disorder—Doxorubicin—bone cancer	0.00136	0.00146	CcSEcCtD
Guanabenz—Leukopenia—Methotrexate—bone cancer	0.00136	0.00146	CcSEcCtD
Guanabenz—Chills—Doxorubicin—bone cancer	0.00136	0.00145	CcSEcCtD
Guanabenz—Nausea—Cisplatin—bone cancer	0.00134	0.00144	CcSEcCtD
Guanabenz—Vision blurred—Epirubicin—bone cancer	0.00134	0.00144	CcSEcCtD
Guanabenz—Cough—Methotrexate—bone cancer	0.00133	0.00142	CcSEcCtD
Guanabenz—Ill-defined disorder—Epirubicin—bone cancer	0.00132	0.00141	CcSEcCtD
Guanabenz—Malnutrition—Doxorubicin—bone cancer	0.00132	0.00141	CcSEcCtD
Guanabenz—Erythema—Doxorubicin—bone cancer	0.00132	0.00141	CcSEcCtD
Guanabenz—Anaemia—Epirubicin—bone cancer	0.00132	0.00141	CcSEcCtD
Guanabenz—Agitation—Epirubicin—bone cancer	0.00131	0.0014	CcSEcCtD
Guanabenz—Flatulence—Doxorubicin—bone cancer	0.0013	0.00139	CcSEcCtD
Guanabenz—Chest pain—Methotrexate—bone cancer	0.00129	0.00139	CcSEcCtD
Guanabenz—Myalgia—Methotrexate—bone cancer	0.00129	0.00139	CcSEcCtD
Guanabenz—Arthralgia—Methotrexate—bone cancer	0.00129	0.00139	CcSEcCtD
Guanabenz—Tension—Doxorubicin—bone cancer	0.00129	0.00138	CcSEcCtD
Guanabenz—Malaise—Epirubicin—bone cancer	0.00128	0.00137	CcSEcCtD
Guanabenz—Discomfort—Methotrexate—bone cancer	0.00128	0.00137	CcSEcCtD
Guanabenz—Nervousness—Doxorubicin—bone cancer	0.00128	0.00137	CcSEcCtD
Guanabenz—Syncope—Epirubicin—bone cancer	0.00128	0.00137	CcSEcCtD
Guanabenz—Leukopenia—Epirubicin—bone cancer	0.00127	0.00136	CcSEcCtD
Guanabenz—Back pain—Doxorubicin—bone cancer	0.00127	0.00136	CcSEcCtD
Guanabenz—Muscle spasms—Doxorubicin—bone cancer	0.00127	0.00136	CcSEcCtD
Guanabenz—Confusional state—Methotrexate—bone cancer	0.00125	0.00134	CcSEcCtD
Guanabenz—Loss of consciousness—Epirubicin—bone cancer	0.00125	0.00134	CcSEcCtD
Guanabenz—Cough—Epirubicin—bone cancer	0.00124	0.00133	CcSEcCtD
Guanabenz—Vision blurred—Doxorubicin—bone cancer	0.00124	0.00133	CcSEcCtD
Guanabenz—Infection—Methotrexate—bone cancer	0.00123	0.00132	CcSEcCtD
Guanabenz—Hypertension—Epirubicin—bone cancer	0.00123	0.00132	CcSEcCtD
Guanabenz—Ill-defined disorder—Doxorubicin—bone cancer	0.00122	0.00131	CcSEcCtD
Guanabenz—Nervous system disorder—Methotrexate—bone cancer	0.00122	0.0013	CcSEcCtD
Guanabenz—Anaemia—Doxorubicin—bone cancer	0.00122	0.0013	CcSEcCtD
Guanabenz—Thrombocytopenia—Methotrexate—bone cancer	0.00122	0.0013	CcSEcCtD
Guanabenz—Myalgia—Epirubicin—bone cancer	0.00121	0.0013	CcSEcCtD
Guanabenz—Chest pain—Epirubicin—bone cancer	0.00121	0.0013	CcSEcCtD
Guanabenz—Arthralgia—Epirubicin—bone cancer	0.00121	0.0013	CcSEcCtD
Guanabenz—Agitation—Doxorubicin—bone cancer	0.00121	0.0013	CcSEcCtD
Guanabenz—Anxiety—Epirubicin—bone cancer	0.00121	0.00129	CcSEcCtD
Guanabenz—Skin disorder—Methotrexate—bone cancer	0.00121	0.00129	CcSEcCtD
Guanabenz—Discomfort—Epirubicin—bone cancer	0.0012	0.00128	CcSEcCtD
Guanabenz—Malaise—Doxorubicin—bone cancer	0.00119	0.00127	CcSEcCtD
Guanabenz—Dry mouth—Epirubicin—bone cancer	0.00118	0.00127	CcSEcCtD
Guanabenz—Anorexia—Methotrexate—bone cancer	0.00118	0.00127	CcSEcCtD
Guanabenz—Syncope—Doxorubicin—bone cancer	0.00118	0.00126	CcSEcCtD
Guanabenz—Leukopenia—Doxorubicin—bone cancer	0.00118	0.00126	CcSEcCtD
Guanabenz—Confusional state—Epirubicin—bone cancer	0.00117	0.00125	CcSEcCtD
Guanabenz—Oedema—Epirubicin—bone cancer	0.00116	0.00124	CcSEcCtD
Guanabenz—Hypotension—Methotrexate—bone cancer	0.00116	0.00124	CcSEcCtD
Guanabenz—Loss of consciousness—Doxorubicin—bone cancer	0.00116	0.00124	CcSEcCtD
Guanabenz—Infection—Epirubicin—bone cancer	0.00115	0.00124	CcSEcCtD
Guanabenz—Cough—Doxorubicin—bone cancer	0.00115	0.00123	CcSEcCtD
Guanabenz—Shock—Epirubicin—bone cancer	0.00114	0.00122	CcSEcCtD
Guanabenz—Nervous system disorder—Epirubicin—bone cancer	0.00114	0.00122	CcSEcCtD
Guanabenz—Thrombocytopenia—Epirubicin—bone cancer	0.00114	0.00122	CcSEcCtD
Guanabenz—Hypertension—Doxorubicin—bone cancer	0.00114	0.00122	CcSEcCtD
Guanabenz—Tachycardia—Epirubicin—bone cancer	0.00113	0.00121	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Methotrexate—bone cancer	0.00113	0.00121	CcSEcCtD
Guanabenz—Skin disorder—Epirubicin—bone cancer	0.00113	0.00121	CcSEcCtD
Guanabenz—Arthralgia—Doxorubicin—bone cancer	0.00112	0.0012	CcSEcCtD
Guanabenz—Chest pain—Doxorubicin—bone cancer	0.00112	0.0012	CcSEcCtD
Guanabenz—Myalgia—Doxorubicin—bone cancer	0.00112	0.0012	CcSEcCtD
Guanabenz—Anxiety—Doxorubicin—bone cancer	0.00112	0.0012	CcSEcCtD
Guanabenz—Paraesthesia—Methotrexate—bone cancer	0.00111	0.00119	CcSEcCtD
Guanabenz—Discomfort—Doxorubicin—bone cancer	0.00111	0.00119	CcSEcCtD
Guanabenz—Anorexia—Epirubicin—bone cancer	0.00111	0.00119	CcSEcCtD
Guanabenz—Dyspnoea—Methotrexate—bone cancer	0.00111	0.00119	CcSEcCtD
Guanabenz—Dry mouth—Doxorubicin—bone cancer	0.0011	0.00117	CcSEcCtD
Guanabenz—Dyspepsia—Methotrexate—bone cancer	0.00109	0.00117	CcSEcCtD
Guanabenz—Hypotension—Epirubicin—bone cancer	0.00109	0.00116	CcSEcCtD
Guanabenz—Confusional state—Doxorubicin—bone cancer	0.00108	0.00116	CcSEcCtD
Guanabenz—Decreased appetite—Methotrexate—bone cancer	0.00108	0.00116	CcSEcCtD
Guanabenz—Oedema—Doxorubicin—bone cancer	0.00107	0.00115	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Methotrexate—bone cancer	0.00107	0.00115	CcSEcCtD
Guanabenz—Fatigue—Methotrexate—bone cancer	0.00107	0.00115	CcSEcCtD
Guanabenz—Infection—Doxorubicin—bone cancer	0.00107	0.00114	CcSEcCtD
Guanabenz—Pain—Methotrexate—bone cancer	0.00106	0.00114	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Epirubicin—bone cancer	0.00106	0.00113	CcSEcCtD
Guanabenz—Shock—Doxorubicin—bone cancer	0.00106	0.00113	CcSEcCtD
Guanabenz—Nervous system disorder—Doxorubicin—bone cancer	0.00105	0.00113	CcSEcCtD
Guanabenz—Thrombocytopenia—Doxorubicin—bone cancer	0.00105	0.00113	CcSEcCtD
Guanabenz—Tachycardia—Doxorubicin—bone cancer	0.00105	0.00112	CcSEcCtD
Guanabenz—Skin disorder—Doxorubicin—bone cancer	0.00104	0.00112	CcSEcCtD
Guanabenz—Paraesthesia—Epirubicin—bone cancer	0.00104	0.00112	CcSEcCtD
Guanabenz—Dyspnoea—Epirubicin—bone cancer	0.00104	0.00111	CcSEcCtD
Guanabenz—Anorexia—Doxorubicin—bone cancer	0.00102	0.0011	CcSEcCtD
Guanabenz—Feeling abnormal—Methotrexate—bone cancer	0.00102	0.0011	CcSEcCtD
Guanabenz—Dyspepsia—Epirubicin—bone cancer	0.00102	0.00109	CcSEcCtD
Guanabenz—Gastrointestinal pain—Methotrexate—bone cancer	0.00101	0.00109	CcSEcCtD
Guanabenz—Decreased appetite—Epirubicin—bone cancer	0.00101	0.00108	CcSEcCtD
Guanabenz—Hypotension—Doxorubicin—bone cancer	0.001	0.00108	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Epirubicin—bone cancer	0.001	0.00107	CcSEcCtD
Guanabenz—Fatigue—Epirubicin—bone cancer	0.001	0.00107	CcSEcCtD
Guanabenz—Constipation—Epirubicin—bone cancer	0.000993	0.00106	CcSEcCtD
Guanabenz—Pain—Epirubicin—bone cancer	0.000993	0.00106	CcSEcCtD
Guanabenz—Urticaria—Methotrexate—bone cancer	0.000986	0.00106	CcSEcCtD
Guanabenz—Abdominal pain—Methotrexate—bone cancer	0.000981	0.00105	CcSEcCtD
Guanabenz—Body temperature increased—Methotrexate—bone cancer	0.000981	0.00105	CcSEcCtD
Guanabenz—Musculoskeletal discomfort—Doxorubicin—bone cancer	0.000979	0.00105	CcSEcCtD
Guanabenz—Paraesthesia—Doxorubicin—bone cancer	0.000965	0.00103	CcSEcCtD
Guanabenz—Dyspnoea—Doxorubicin—bone cancer	0.000958	0.00103	CcSEcCtD
Guanabenz—Feeling abnormal—Epirubicin—bone cancer	0.000957	0.00103	CcSEcCtD
Guanabenz—Gastrointestinal pain—Epirubicin—bone cancer	0.00095	0.00102	CcSEcCtD
Guanabenz—Dyspepsia—Doxorubicin—bone cancer	0.000946	0.00101	CcSEcCtD
Guanabenz—Decreased appetite—Doxorubicin—bone cancer	0.000934	0.001	CcSEcCtD
Guanabenz—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000928	0.000994	CcSEcCtD
Guanabenz—Fatigue—Doxorubicin—bone cancer	0.000927	0.000992	CcSEcCtD
Guanabenz—Urticaria—Epirubicin—bone cancer	0.000923	0.000988	CcSEcCtD
Guanabenz—Pain—Doxorubicin—bone cancer	0.000919	0.000984	CcSEcCtD
Guanabenz—Constipation—Doxorubicin—bone cancer	0.000919	0.000984	CcSEcCtD
Guanabenz—Body temperature increased—Epirubicin—bone cancer	0.000918	0.000983	CcSEcCtD
Guanabenz—Abdominal pain—Epirubicin—bone cancer	0.000918	0.000983	CcSEcCtD
Guanabenz—Hypersensitivity—Methotrexate—bone cancer	0.000914	0.000979	CcSEcCtD
Guanabenz—Asthenia—Methotrexate—bone cancer	0.00089	0.000954	CcSEcCtD
Guanabenz—Feeling abnormal—Doxorubicin—bone cancer	0.000886	0.000948	CcSEcCtD
Guanabenz—Gastrointestinal pain—Doxorubicin—bone cancer	0.000879	0.000941	CcSEcCtD
Guanabenz—Pruritus—Methotrexate—bone cancer	0.000878	0.00094	CcSEcCtD
Guanabenz—Hypersensitivity—Epirubicin—bone cancer	0.000856	0.000916	CcSEcCtD
Guanabenz—Urticaria—Doxorubicin—bone cancer	0.000854	0.000914	CcSEcCtD
Guanabenz—CYP1A2—Fatty Acid Omega Oxidation—CYP3A4—bone cancer	0.000852	0.0186	CbGpPWpGaD
Guanabenz—Abdominal pain—Doxorubicin—bone cancer	0.00085	0.00091	CcSEcCtD
Guanabenz—Body temperature increased—Doxorubicin—bone cancer	0.00085	0.00091	CcSEcCtD
Guanabenz—Diarrhoea—Methotrexate—bone cancer	0.000849	0.000909	CcSEcCtD
Guanabenz—Asthenia—Epirubicin—bone cancer	0.000833	0.000893	CcSEcCtD
Guanabenz—Pruritus—Epirubicin—bone cancer	0.000822	0.00088	CcSEcCtD
Guanabenz—Dizziness—Methotrexate—bone cancer	0.000821	0.000879	CcSEcCtD
Guanabenz—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—bone cancer	0.000798	0.0174	CbGpPWpGaD
Guanabenz—Diarrhoea—Epirubicin—bone cancer	0.000795	0.000851	CcSEcCtD
Guanabenz—Hypersensitivity—Doxorubicin—bone cancer	0.000792	0.000848	CcSEcCtD
Guanabenz—Vomiting—Methotrexate—bone cancer	0.000789	0.000845	CcSEcCtD
Guanabenz—Rash—Methotrexate—bone cancer	0.000783	0.000838	CcSEcCtD
Guanabenz—Dermatitis—Methotrexate—bone cancer	0.000782	0.000837	CcSEcCtD
Guanabenz—Headache—Methotrexate—bone cancer	0.000778	0.000833	CcSEcCtD
Guanabenz—CYP1A2—Estrogen metabolism—CYP3A4—bone cancer	0.000776	0.0169	CbGpPWpGaD
Guanabenz—Asthenia—Doxorubicin—bone cancer	0.000771	0.000826	CcSEcCtD
Guanabenz—Dizziness—Epirubicin—bone cancer	0.000768	0.000823	CcSEcCtD
Guanabenz—Pruritus—Doxorubicin—bone cancer	0.00076	0.000814	CcSEcCtD
Guanabenz—CYP1A2—Aflatoxin activation and detoxification—CYP3A4—bone cancer	0.000743	0.0162	CbGpPWpGaD
Guanabenz—Vomiting—Epirubicin—bone cancer	0.000738	0.000791	CcSEcCtD
Guanabenz—Nausea—Methotrexate—bone cancer	0.000737	0.00079	CcSEcCtD
Guanabenz—Diarrhoea—Doxorubicin—bone cancer	0.000735	0.000788	CcSEcCtD
Guanabenz—Rash—Epirubicin—bone cancer	0.000732	0.000784	CcSEcCtD
Guanabenz—Dermatitis—Epirubicin—bone cancer	0.000732	0.000784	CcSEcCtD
Guanabenz—Headache—Epirubicin—bone cancer	0.000728	0.000779	CcSEcCtD
Guanabenz—CYP1A2—Xenobiotics—CYP3A4—bone cancer	0.000713	0.0155	CbGpPWpGaD
Guanabenz—Dizziness—Doxorubicin—bone cancer	0.000711	0.000761	CcSEcCtD
Guanabenz—Nausea—Epirubicin—bone cancer	0.00069	0.000739	CcSEcCtD
Guanabenz—CYP1A2—Tamoxifen metabolism—CYP3A4—bone cancer	0.000686	0.0149	CbGpPWpGaD
Guanabenz—Vomiting—Doxorubicin—bone cancer	0.000683	0.000732	CcSEcCtD
Guanabenz—Rash—Doxorubicin—bone cancer	0.000678	0.000726	CcSEcCtD
Guanabenz—Dermatitis—Doxorubicin—bone cancer	0.000677	0.000725	CcSEcCtD
Guanabenz—Headache—Doxorubicin—bone cancer	0.000673	0.000721	CcSEcCtD
Guanabenz—Nausea—Doxorubicin—bone cancer	0.000638	0.000684	CcSEcCtD
Guanabenz—CYP1A2—Metapathway biotransformation—CYP4V2—bone cancer	0.000636	0.0139	CbGpPWpGaD
Guanabenz—ADRA2C—Regulation of insulin secretion—GNA11—bone cancer	0.000597	0.013	CbGpPWpGaD
Guanabenz—ADRA2A—Regulation of insulin secretion—GNA11—bone cancer	0.000485	0.0106	CbGpPWpGaD
Guanabenz—ADRA2C—Integration of energy metabolism—GNA11—bone cancer	0.000469	0.0102	CbGpPWpGaD
Guanabenz—ADRA2B—G alpha (i) signalling events—RGS1—bone cancer	0.000468	0.0102	CbGpPWpGaD
Guanabenz—ADRA2B—G alpha (i) signalling events—GRM4—bone cancer	0.000468	0.0102	CbGpPWpGaD
Guanabenz—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP3A4—bone cancer	0.000466	0.0102	CbGpPWpGaD
Guanabenz—ADRA2C—G alpha (i) signalling events—RGS1—bone cancer	0.000437	0.00953	CbGpPWpGaD
Guanabenz—ADRA2C—G alpha (i) signalling events—GRM4—bone cancer	0.000437	0.00953	CbGpPWpGaD
Guanabenz—CYP1A2—Estrogen Receptor Pathway—JUN—bone cancer	0.000402	0.00876	CbGpPWpGaD
Guanabenz—ADRA2A—Integration of energy metabolism—GNA11—bone cancer	0.000381	0.0083	CbGpPWpGaD
Guanabenz—CYP1A2—Tryptophan metabolism—CYP3A4—bone cancer	0.000366	0.00798	CbGpPWpGaD
Guanabenz—ADRA2A—G alpha (i) signalling events—RGS1—bone cancer	0.000355	0.00774	CbGpPWpGaD
Guanabenz—ADRA2A—G alpha (i) signalling events—GRM4—bone cancer	0.000355	0.00774	CbGpPWpGaD
Guanabenz—ADRA2B—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.0003	0.00654	CbGpPWpGaD
Guanabenz—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP3A4—bone cancer	0.000296	0.00645	CbGpPWpGaD
Guanabenz—CYP1A2—Oxidation by Cytochrome P450—CYP3A4—bone cancer	0.000292	0.00636	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR ligand binding—GRM4—bone cancer	0.000283	0.00618	CbGpPWpGaD
Guanabenz—ADRA2C—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000281	0.00611	CbGpPWpGaD
Guanabenz—ADRA2B—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000275	0.00599	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR ligand binding—GRM4—bone cancer	0.000265	0.00577	CbGpPWpGaD
Guanabenz—ADRA2C—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000257	0.00559	CbGpPWpGaD
Guanabenz—ADRA2B—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000249	0.00543	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR ligand binding—GRM1—bone cancer	0.000246	0.00535	CbGpPWpGaD
Guanabenz—CYP1A2—Phase 1 - Functionalization of compounds—CYP3A4—bone cancer	0.00024	0.00523	CbGpPWpGaD
Guanabenz—ADRA2C—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000233	0.00507	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR ligand binding—GRM1—bone cancer	0.00023	0.005	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—SPARC—bone cancer	0.000228	0.00497	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR ligand binding—GRM4—bone cancer	0.000215	0.00469	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—GNA11—bone cancer	0.000208	0.00454	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor—RB1—bone cancer	0.000197	0.0043	CbGpPWpGaD
Guanabenz—ADRA2A—Platelet activation, signaling and aggregation—IL3—bone cancer	0.000189	0.00412	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR ligand binding—GRM1—bone cancer	0.000186	0.00406	CbGpPWpGaD
Guanabenz—CYP1A2—Phase II conjugation—GSTP1—bone cancer	0.000186	0.00406	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR ligand binding—SMO—bone cancer	0.000173	0.00377	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—NDUFA12—bone cancer	0.00017	0.00371	CbGpPWpGaD
Guanabenz—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000168	0.00367	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000162	0.00353	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR ligand binding—SMO—bone cancer	0.000162	0.00352	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—GRM4—bone cancer	0.00016	0.00349	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—RGS1—bone cancer	0.00016	0.00349	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—SPARC—bone cancer	0.000155	0.00337	CbGpPWpGaD
Guanabenz—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000152	0.00331	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—RGS1—bone cancer	0.00015	0.00326	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—GRM4—bone cancer	0.00015	0.00326	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	0.000146	0.00319	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—GRM4—bone cancer	0.000145	0.00317	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—RGS1—bone cancer	0.000145	0.00317	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—SPARC—bone cancer	0.000145	0.00315	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—GNA11—bone cancer	0.000142	0.00309	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—NT5C3A—bone cancer	0.000141	0.00308	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—GRM1—bone cancer	0.000139	0.00303	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—NDUFA12—bone cancer	0.000138	0.00302	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—RGS1—bone cancer	0.000136	0.00296	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—GRM4—bone cancer	0.000136	0.00296	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—GNA11—bone cancer	0.000132	0.00288	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR ligand binding—SMO—bone cancer	0.000131	0.00286	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—GRM1—bone cancer	0.00013	0.00283	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—IL3—bone cancer	0.000128	0.0028	CbGpPWpGaD
Guanabenz—CYP1A2—Biological oxidations—CYP3A4—bone cancer	0.000127	0.00278	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—GRM1—bone cancer	0.000126	0.00275	CbGpPWpGaD
Guanabenz—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	0.000126	0.00274	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—GRM4—bone cancer	0.000122	0.00265	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—RGS1—bone cancer	0.000122	0.00265	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—IL3—bone cancer	0.00012	0.00261	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—GRM1—bone cancer	0.000118	0.00257	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—SPARC—bone cancer	0.000117	0.00256	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	0.000115	0.00251	CbGpPWpGaD
Guanabenz—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	0.000115	0.00251	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—NT5C3A—bone cancer	0.000115	0.0025	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—GRM4—bone cancer	0.00011	0.0024	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—RGS1—bone cancer	0.00011	0.0024	CbGpPWpGaD
Guanabenz—CYP1A2—Biological oxidations—GSTP1—bone cancer	0.000109	0.00238	CbGpPWpGaD
Guanabenz—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	0.000108	0.00234	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—GNA11—bone cancer	0.000107	0.00234	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—GRM1—bone cancer	0.000105	0.0023	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—IL3—bone cancer	9.74e-05	0.00212	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—GRM1—bone cancer	9.57e-05	0.00208	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—GNA11—bone cancer	8.95e-05	0.00195	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—SMO—bone cancer	8.89e-05	0.00194	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—RGS1—bone cancer	8.59e-05	0.00187	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—GRM4—bone cancer	8.59e-05	0.00187	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—PLAU—bone cancer	8.42e-05	0.00183	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—GNA11—bone cancer	8.36e-05	0.00182	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—SMO—bone cancer	8.3e-05	0.00181	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—GNA11—bone cancer	8.13e-05	0.00177	CbGpPWpGaD
Guanabenz—ADRA2B—GPCR downstream signaling—IL3—bone cancer	8.11e-05	0.00177	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—GRM4—bone cancer	8.03e-05	0.00175	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—RGS1—bone cancer	8.03e-05	0.00175	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—PLAU—bone cancer	7.87e-05	0.00171	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NDUFA12—bone cancer	7.64e-05	0.00166	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—GNA11—bone cancer	7.59e-05	0.00165	CbGpPWpGaD
Guanabenz—ADRA2C—GPCR downstream signaling—IL3—bone cancer	7.58e-05	0.00165	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—GRM1—bone cancer	7.45e-05	0.00162	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—IL3—bone cancer	7.37e-05	0.00161	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—GRM1—bone cancer	6.96e-05	0.00152	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—IL3—bone cancer	6.88e-05	0.0015	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—GNA11—bone cancer	6.79e-05	0.00148	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—SMO—bone cancer	6.74e-05	0.00147	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—GRM4—bone cancer	6.52e-05	0.00142	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—RGS1—bone cancer	6.52e-05	0.00142	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—PLAU—bone cancer	6.39e-05	0.00139	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—NT5C3A—bone cancer	6.33e-05	0.00138	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—ENO2—bone cancer	6.19e-05	0.00135	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—GNA11—bone cancer	6.17e-05	0.00134	CbGpPWpGaD
Guanabenz—ADRA2A—GPCR downstream signaling—IL3—bone cancer	6.16e-05	0.00134	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—DHFR—bone cancer	5.74e-05	0.00125	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—GRM1—bone cancer	5.65e-05	0.00123	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—IL3—bone cancer	5.59e-05	0.00122	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GNA11—bone cancer	5.36e-05	0.00117	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—SMO—bone cancer	5.25e-05	0.00114	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—ENO2—bone cancer	5.02e-05	0.00109	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—SMO—bone cancer	4.9e-05	0.00107	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—CYP3A4—bone cancer	4.86e-05	0.00106	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—GNA11—bone cancer	4.8e-05	0.00105	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—DHFR—bone cancer	4.66e-05	0.00102	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—GNA11—bone cancer	4.48e-05	0.000977	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—ATF1—bone cancer	4.46e-05	0.000972	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GNA11—bone cancer	4.36e-05	0.000949	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IL3—bone cancer	4.35e-05	0.000948	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—ATF1—bone cancer	4.17e-05	0.000908	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—GSTP1—bone cancer	4.16e-05	0.000906	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IL3—bone cancer	4.07e-05	0.000886	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—SMO—bone cancer	3.98e-05	0.000868	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—CYP3A4—bone cancer	3.95e-05	0.00086	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TGFBR2—bone cancer	3.72e-05	0.000811	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—GNA11—bone cancer	3.64e-05	0.000794	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—IGF1R—bone cancer	3.5e-05	0.000763	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TGFBR2—bone cancer	3.48e-05	0.000758	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—ATF1—bone cancer	3.39e-05	0.000738	CbGpPWpGaD
Guanabenz—ADRA2B—Hemostasis—TP53—bone cancer	3.39e-05	0.000738	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—GSTP1—bone cancer	3.38e-05	0.000736	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IL3—bone cancer	3.3e-05	0.000719	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—IGF1R—bone cancer	3.27e-05	0.000713	CbGpPWpGaD
Guanabenz—ADRA2C—Hemostasis—TP53—bone cancer	3.16e-05	0.000689	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TGFBR2—bone cancer	2.82e-05	0.000615	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—ENO2—bone cancer	2.77e-05	0.000604	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—IGF1R—bone cancer	2.66e-05	0.000579	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—DHFR—bone cancer	2.57e-05	0.000561	CbGpPWpGaD
Guanabenz—ADRA2A—Hemostasis—TP53—bone cancer	2.57e-05	0.00056	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—KIT—bone cancer	2.54e-05	0.000553	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GNA11—bone cancer	2.4e-05	0.000524	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—BRAF—bone cancer	2.39e-05	0.00052	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—KIT—bone cancer	2.37e-05	0.000517	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling by GPCR—EGFR—bone cancer	2.31e-05	0.000504	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—BRAF—bone cancer	2.23e-05	0.000486	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—CYP3A4—bone cancer	2.18e-05	0.000475	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.17e-05	0.000473	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling by GPCR—EGFR—bone cancer	2.16e-05	0.000471	CbGpPWpGaD
Guanabenz—ADRA2C—Metabolism—PTGS2—bone cancer	2.15e-05	0.000469	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MDM2—bone cancer	2e-05	0.000436	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—KIT—bone cancer	1.93e-05	0.00042	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MDM2—bone cancer	1.87e-05	0.000407	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—GSTP1—bone cancer	1.86e-05	0.000406	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—BRAF—bone cancer	1.81e-05	0.000395	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling by GPCR—EGFR—bone cancer	1.76e-05	0.000383	CbGpPWpGaD
Guanabenz—ADRA2A—Metabolism—PTGS2—bone cancer	1.75e-05	0.000381	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—JUN—bone cancer	1.74e-05	0.000379	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—MMP9—bone cancer	1.69e-05	0.000369	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—JUN—bone cancer	1.62e-05	0.000354	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—MMP9—bone cancer	1.58e-05	0.000344	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MDM2—bone cancer	1.52e-05	0.000331	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—EGFR—bone cancer	1.37e-05	0.000298	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—JUN—bone cancer	1.32e-05	0.000287	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—MMP9—bone cancer	1.28e-05	0.00028	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—EGFR—bone cancer	1.28e-05	0.000278	CbGpPWpGaD
Guanabenz—ADRA2B—Signaling Pathways—TP53—bone cancer	1.15e-05	0.00025	CbGpPWpGaD
Guanabenz—ADRA2C—Signaling Pathways—TP53—bone cancer	1.07e-05	0.000234	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—EGFR—bone cancer	1.04e-05	0.000226	CbGpPWpGaD
Guanabenz—CYP1A2—Metabolism—PTGS2—bone cancer	9.66e-06	0.00021	CbGpPWpGaD
Guanabenz—ADRA2A—Signaling Pathways—TP53—bone cancer	8.71e-06	0.00019	CbGpPWpGaD
